Celularity regains key Nasdaq listing standards
Celularity has regained Nasdaq compliance on bid price and market value, but its Nasdaq deficiency tied to delayed SEC periodic reports is still unresolved.
Rhea-AI Filing Summary
Celularity Inc. (CELU) reports that on September 11, 2026 it received written notice from Nasdaq that it has regained compliance with both the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). Nasdaq has informed Celularity that these compliance matters are now closed. Celularity also discloses that a previously reported deficiency under Nasdaq Listing Rule 5250(c)(1), relating to delayed filing of periodic reports with the SEC, remains outstanding, and the company continues working to complete those filings and regain compliance with Nasdaq’s periodic reporting requirement.
Positive
- Regained Nasdaq compliance on trading standards: Celularity is again in compliance with the Nasdaq minimum bid price requirement under Rule 5550(a)(2) and the minimum market value of listed securities requirement under Rule 5550(b)(2), and Nasdaq has closed these matters.
Negative
- Nasdaq reporting deficiency still open: Celularity’s deficiency under Nasdaq Listing Rule 5250(c)(1), related to delayed SEC periodic filings, remains outstanding while the company works to complete the delayed reports.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Notification date: September 11, 2026
Nasdaq Listing Rule 5550(a)(2): Minimum bid price requirement
Nasdaq Listing Rule 5550(b)(2): Minimum market value of listed securities requirement
+1 more
4 metrics
Notification date
September 11, 2026
Date Nasdaq notified Celularity it had regained compliance with certain listing requirements
Nasdaq Listing Rule 5550(a)(2)
Minimum bid price requirement
Rule with which Celularity has regained compliance
Nasdaq Listing Rule 5550(b)(2)
Minimum market value of listed securities requirement
Rule with which Celularity has regained compliance
Nasdaq Listing Rule 5250(c)(1)
Periodic reporting requirement deficiency
Remaining Nasdaq deficiency related to delayed SEC periodic reports
Key Terms
minimum bid price requirement, minimum market value of listed securities requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5550(b)(2), +2 more
6 terms
minimum bid price requirement market
"regained compliance with the minimum bid price requirement under Nasdaq Listing Rule"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
minimum market value of listed securities requirement market
"and the minimum market value of listed securities requirement under Nasdaq Listing"
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5550(b)(2) regulatory
"minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2)"
Nasdaq Listing Rule 5250(c)(1) regulatory
"previously disclosed deficiency under Nasdaq Listing Rule 5250(c)(1), relating"
Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.
periodic reports financial
"relating to the delayed filing of its periodic reports with the Securities"
Regularly scheduled documents that a publicly traded company must provide to disclose its financial results, business operations, risks and significant events — like a report card showing revenue, profits, cash flow and key changes over a set period. Investors use these reports to judge a company's health and trends, compare performance over time, and make informed buy, hold or sell decisions; they act as a routine check-up for financial transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq listing requirements has Celularity (CELU) now regained compliance with?
Celularity has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Listing Rule 5550(b)(2). Nasdaq has advised the company that both of these compliance matters are now closed.
Does Celularity (CELU) still have any outstanding Nasdaq deficiencies?
Yes. Celularity’s previously disclosed deficiency under Nasdaq Listing Rule 5250(c)(1), which relates to delayed filing of its periodic reports with the SEC, remains outstanding. The company states it continues to work to complete its delayed filings and regain compliance with Nasdaq’s periodic reporting requirement.
What is the significance of Nasdaq Listing Rule 5550(a)(2) for Celularity (CELU)?
Nasdaq Listing Rule 5550(a)(2) sets the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Celularity reports it has regained compliance with this requirement, and Nasdaq has closed the related compliance matter.
What does Nasdaq Listing Rule 5550(b)(2) require and how does it affect Celularity (CELU)?
Nasdaq Listing Rule 5550(b)(2) addresses the minimum market value of listed securities requirement for continued listing. Celularity states Nasdaq has confirmed the company has regained compliance with this requirement and that the matter is now closed.
What ongoing steps is Celularity (CELU) taking regarding its SEC filings?
Celularity states it continues to work to complete its delayed periodic filings with the SEC, aiming to resolve its outstanding deficiency under Nasdaq Listing Rule 5250(c)(1) and regain full compliance with Nasdaq’s periodic reporting requirement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
